https://www.prnewswire.com/news-releases/karyopharm-receives-orphan-drug-designation-from-fda-for-eltanexor-for-the-treatment-of-myelodysplastic-syndromes-301466251.html
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of...
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...
orphan drug designation